Eravacycline is an antibiotic under development for the treatment of multidrug-resistant (MDR) infections, including those caused by MDR Gram-negative bacteria. Eravacycline is a novel, fully synthetic tetracycline antibiotic. It is a broad-spectrum intravenous and oral antibiotic.
Tetraphase Pharmaceuticals is currently investigating the safety and efficacy of eravacycline in a Phase 3 program called IGNITE (Investigating Gram-negative Infections Treated with Eravacycline) for the treatment of complicated intra-abdominal infections (cIAI)(IGNITE 1) and complicated urinary tract infections (cUTI)(IGNITE 2). The company expects to file for U.S. regulatory approval for eravacycline for both indications by the end of 2015.
Patient Ratings for
How was your experience with ?
Eravacycline Drug Class
Eravacycline is part of the drug class: